What did @toreegetstiny actually say?
Honestly? Not much, medically speaking. The transcript is a fragment of song lyrics, "If this world was mine, I'd take your dreams and make," stitched together with filler sounds. There are no spoken health claims here. What we're working with is a before-and-after transformation video hashtagged with #glp1 and #pcos, which is itself a form of implicit messaging even when the creator says nothing clinical out loud.
Before-and-after content communicates through implication. The combination of a visible body transformation, a GLP-1 hashtag, and a PCOS tag tells viewers: this medication worked for this condition in this person's body. That's a claim, even if it's never spoken. And it's worth examining on those terms rather than pretending the video makes no assertion at all.
Does the science back this up?
The implicit claim, that GLP-1 receptor agonists can support weight loss in people with PCOS, is actually reasonably well-supported. The problem is that social media flattens all the nuance out of it.
A 2023 systematic review by Cena et al. in Nutrients found that GLP-1 agonists including semaglutide and liraglutide showed meaningful reductions in body weight and BMI in women with PCOS, along with improvements in insulin resistance and androgen levels. Earlier work by Jensterle et al. (2019, Reproductive Biology and Endocrinology) found liraglutide outperformed metformin for weight loss in PCOS patients over 12 weeks. These aren't fringe findings.
But individual before-and-after results vary enormously based on dose, duration, baseline metabolic health, diet, and activity level. A transformation video doesn't tell you any of that. It tells you one person's outcome over an unspecified timeline, which is anecdote, not evidence.
What did they get wrong (or right)?
To be fair, the creator didn't make any verifiable medical errors because they didn't make any medical statements. Credit where it's due: this is not a video pushing a specific dose, comparing compounded semaglutide to Wegovy, or claiming GLP-1 cures PCOS. It's a transformation post. That restraint, intentional or not, matters.
What's worth pushing back on is the broader pattern this video participates in. The #pcos hashtag next to a dramatic weight-loss result feeds a narrative that PCOS is primarily a weight problem with a pharmaceutical fix. It isn't. PCOS is a complex endocrine disorder involving ovulatory dysfunction, androgen excess, and insulin dysregulation. Weight loss through any mechanism can improve symptoms, but it doesn't treat the underlying condition. Framing GLP-1 results as a PCOS transformation without that context can mislead people about what these medications actually do.
- GLP-1 agonists are not FDA-approved specifically for PCOS treatment.
- Weight loss improves PCOS symptoms in many patients but is not curative.
- Not everyone with PCOS has obesity or would be a candidate for these medications.
What should you actually know?
If you have PCOS and you're curious about GLP-1 medications after seeing content like this, here's the honest version: the data is encouraging but still developing, and your situation is individual.
Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are approved for weight management and type 2 diabetes, not PCOS specifically. Prescribing them for PCOS is off-label, which is legal and sometimes clinically reasonable, but it means the evidence base is thinner than for their approved indications. A 2022 RCT by Frías et al. in The New England Journal of Medicine confirmed tirzepatide's weight loss superiority over semaglutide in a broad population, but PCOS-specific data for tirzepatide remains limited.
Anyone considering these medications should have a real clinical evaluation, not a 60-second video as their primary information source. That includes lab work, a conversation about baseline metabolic health, and realistic expectations about what weight loss does and doesn't resolve in PCOS. A transformation post is someone's highlight reel. It is not a treatment protocol.